Skip to content
FDA Approval: Maintenance Lurbinectedin for SCLC episode artwork

Oct 7, 2025 37 min

FDA Approval: Maintenance Lurbinectedin for SCLC

from Lung Cancer Considered Hosted by IASLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC. Guest: Dr. Hossein Borghaei, DO, MS Chief, Division of Thoracic Medical Oncology Professor, Department of Hematology/Oncology Fox Chase Cancer Center

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

FDA Approval: Maintenance Lurbinectedin for SCLC

0:00 37:53

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Lung Cancer Considered?

This episode is 37 minutes long.

When was this Lung Cancer Considered episode published?

This episode was published on October 7, 2025.

Can I download this Lung Cancer Considered episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.